natgillin/translations-raw huggingface dataset:
The COPD clinical development programme included a 12-week (HZC113107), two 6-month (HZC112206, HZC112207) and two one-year (HZC102970, HZC102871) randomised controlled studies in patients with a clinical diagnosis of COPD.
Program kliničnega razvoja pri KOPB je obsegal eno 12-tedensko (HZC113107), dve 6-mesečni (HZC112206, HZC112207) in dve 1-letni (HZC102970, HZC102871) randomizirani kontrolirani študiji pri bolnikih s klinično diagnozo KOPB.
The COPD patients treated with abatacept developed adverse reactions more frequently than those treated with placebo (51.4% vs.
Pri bolnikih s KOPB, ki so prejemali abatacept, so bili neželeni učinki pogostejši kot pri bolnikih, ki so prejemali placebo (51,4% v primerjavi s 47,1%).
The cord affecting a selected primary joint received up to 3 injections of 0.58 mg of Xiapex or placebo.
V vozlič, ki je prizadel določen primarni sklep, so injicirali do 3 injekcije po 0,58 mg zdravila Xiapex ali placebo.
The cords in the palm of patients with Dupuytren’s contracture and the plaques in Peyronie’s disease are made of fibres of a protein called collagen.
Vozliči v dlani bolnikov z Dupuytrenovo kontrakturo in plaki pri Peyroniejevi bolezni so iz vlaken beljakovine, imenovane kolagen.
The Coronary Drug Project, a five year study completed in 1975, showed that nicotinic acid had a statistically significant benefit in decreasing nonfatal, recurrent myocardial infarctions (MI) in men 30 to 64 years old with a history of MI.
Pet-letna študija Coronary Drug Project, ki se je končala leta 1975, je pokazala, da nikotinska kislina statistično značilno pripomore k zmanjšanju števila neusodnih ponovnih miokardnih infarktov (MI) pri moških od 30. do
The correct dose is determined individually for each cat depending on weight and needs to be adjusted depending on the response to treatment.
Ustrezni odmerek se določi glede na telesno maso posamezne mačke in ga je treba prilagajati glede na odziv na zdravljenje.
The correct dose will be calculated by your doctor and consists of a total of 6 mg of asfotase alfa per kg of body weight every week, administered by injection under the skin (subcutaneous), (see the dosing chart below for detailed information on the volume to be injected, and the type of vials to be used, based on your weight).
Pravilni odmerek bo zdravnik izračunal in je sestavljen iz skupaj 6 mg asfotaze alfa na kg telesne mase vsak teden, dan v obliki podkožne (subkutane) injekcije (glejte razpredelnico odmerjanja v nadaljevanju glede natančnih podatkov o volumnu, ki ga je treba vbrizgati, in vrsti vial, ki jo je treba uporabiti, na podlagi vaše telesne mase).
The correct method of releasing the tablet from the blister is:
Pravilen način odstranitve tablete iz pretisnega omota je:
The correct number of sachets your doctor has prescribed (supplied in the kit)
ustrezno število vrečic, kot vam je predpisal zdravnik (ki so v kompletu)
The correct number of tablets or half tablets to use is calculated based on the dog’s weight.
Število potrebnih tablet ali polovičk tablet se določi na podlagi telesne mase psa.
The correct way to prepare the vaccine prior to administration.
Pravilno pripravo cepiva pred uporabo.
The corresponding 90% confidence intervals about the ratios of month 6-to-baseline for the above pharmacokinetic parameters were within the equivalence window of 80% to 125%.
Ustrezni 90 % intervali zaupanja okrog kvocientov geometrijskih povprečij najmanjših kvadratov farmakokinetike po 6 mesecih proti izhodišču za zgoraj navedene farmakokinetične parametre so bili znotraj ekvivalenčnega okna med 80 % in 125 %.
The corresponding 90% confidence intervals about the ratios of ReFacto AF to ReFacto geometric means were within the bioequivalence window of 80% to 125%, demonstrating bioequivalence of ReFacto AF to ReFacto.
Ustrezni 90 % intervali zaupanja okrog kvocientov geometrijskih povprečij najmanjših kvadratov zdravila ReFacto AF proti zdravilu ReFacto so bili znotraj bioekvivalenčnega okna med 80 % in 125 %, kar je pokazalo bioekvivalenco zdravila ReFacto AF proti zdravilu ReFacto.
The corresponding amount of Nplate solution to inject = 75 µg x 1 ml = 0.15 ml
Ustrezna količina raztopine Nplate za injiciranje = 75 µg x 1 ml = 0,15 ml
The corresponding bar-code label must be put on the data sheet for patient documentation.
Ustrezno nalepko s črtno kodo je treba nalepiti tudi na vaš podatkovni list.
The corresponding bar-code label must be put on the data sheet for patient documentation.
Vse epruvete se namestijo v originalno ovojnino, ki se jo zapre s preostalo nalepko.
The corresponding clearance in patients in the lower age group was also higher, which is consistent with previous observations.
Tudi ustrezen očistek je bil višji pri bolnikih v skupini z nižjo starostjo, kar se ujema s prejšnjimi opažanji.
The corresponding difference at the 1000 mg twice-daily dose was 25%.
Razlika pri odmerku 1000 mg dvakrat na dan je bila 25 %.
The corresponding doses for both formulations are shown in the table below.
V spodnji preglednici so prikazani ustrezni odmerki za obe formulaciji.
The corresponding elimination half-life remained almost unchanged within a range of 349 to 378 h (approximately 14.5 to 15.8 days).
Ustrezna razpolovna doba izločanja je ostala skoraj nespremenjena v razponu 349 do 378 h (približno 14,5 do 15,8 dni).
The corresponding figures for congestive heart failure (CHF), which was less accurately assessed, were 0% for Myocet + CPA versus 3% for doxorubicin + CPA, and 2% for Myocet versus 8% for doxorubicin.
Rezultati za kongestivno srčno odpoved (CHF – »Congestive Heart Failure«), ki so jo ocenjevali manj natančno, so bili 0 % za kombinacijo zdravila Myocet in CPA, 3 % za kombinacijo doksorubicina in CPA ter 2 % za zdravilo Myocet in 8 % za doksorubicin.
The corresponding increase in unbound ibrutinib exposure (AUCunbound, last) is estimated to be 4.1-, 9.8-, and 13-fold in subjects with mild, moderate, and severe hepatic impairment, respectively (see section 4.2).
Ocenjujejo, da pri bolnikih z blago, zmerno oziroma hudo okvaro jeter pride do 4,1-kratnega, 9,8-kratnega oziroma 13-kratnega povečanja izpostavljenosti nevezanemu ibrutinibu (AUCunbound, last) (glejte poglavje 4.2).
The corresponding negative predictive value and positive predictive value for NeoSpect in association with chest X-ray were 96-98% and 61- 78% respectively.
Ustrezna negativna in pozitivna napovedna vrednost za NeoSpect v povezavi z rentgensko sliko prsnega koša je bila 96-98% oziroma 61-78%.
The corresponding plasma Cmax values were 24 ng/ml and 47 ng/ml, respectively.
Ustrezni vrednosti Cmax v plazmi sta bili 24 ng/ml in 47 ng/ml.
The corresponding results for the oral solution in the same clinical study were Cmin,ss 5.40  2.50 ng/mL, Cmax,ss 14.4  5.3 ng/mL, tmax,ss 2.12  0.84 hours, AUC,ss 194  78 ng.h/mL, CL/F/W 173  50 mL/h/kg.
Ustrezne vrednosti po uporabi peroralne raztopine v isti klinični študiji so bile naslednje: Cmin,ss 5,40 ± 2,50 ng/ml; Cmax,ss 14,4± 5,3 ng/ml; tmax,ss 2,12 ± 0,84 ur; AUC,ss 194 ± 78 ng.h/ml; CL/F/W 173 ± 50 ml/h/kg.
The corresponding risk is 0.3% in patients having the most common genotype (TT) (See section 5.2).
Tveganje pri bolnikih z najpogostejšim genotipom (TT) je 0,3 % (glejte poglavje 5.2).
The corresponding values in the control group were 28.5 (71%) µg·hr/ml and 4.3 (68%) µg/ml.
Ustrezni vrednosti v kontrolni skupini sta bili 28,5 (71 %) µg·hr/ml in 4,3 (68 %) µg/ml.
The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day (see section 4.4).
Kortikosteroid naj ustreza 4 mg deksametazona, danega peroralno dvakrat dnevno (glejte poglavje 4.4).
the corticosteroids prednisolone and methylprednisolone, belonging to the class of corticosteroids used to treat inflammations or suppress the immune system (e.g. in transplant rejection) nefazodone, used to treat depression
kortikosteroida prednizolon in metilprednizolon, ki spadata v skupino kortikosteroidov, ki se uporabljajo za zdravljenje vnetij ali za zaviranje imunskega sistema (npr. pri zavrnitvi presadka),
The cough may last for 1-2 months or longer.
Kašelj lahko traja 1 – 2 meseca ali dlje.
The cough may last for 1-2 months or longer.
Kašelj lahko traja 1–2 meseca ali dlje.
the cough suppressant dextromethorphan sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine
zdravilo za pomirjanje kašlja dekstrometorfan simpatikomimetiki, kot so tisti, ki so prisotni v kapljicah za oči, nosnih ali peroralnih dekongestivih in zdravila proti prehladu, ki vsebujejo efedrin ali psevdoefedrin.
The COUNTDOWN-CLOCK symbol is displayed together with the LOCK- symbol.
Simbol ODŠTEVAJOČE URE se prikaže skupaj s simbolom KLJUČAVNICE.
The counter will stay on the number “2”.
Števec bo ostal na številu “2”.
The counter will stay on the number “8”.
Števec bo ostal na številu “8”.
The course of pre- existing infections may be aggravated.
Potek obstoječih okužb se lahko poslabša.
The cover letter to the healthcare professional should explain that the purpose of the educational materials is to reduce the risk of medication error due to the availability of multiple tablets and dose strengths, and it should provide a list of the contents of the Prescriber Kit.
Spremni dopis zdravstvenim delavcem mora vsebovati razlago, da je namen tega izobraževalnega gradiva zmanjševanje napak pri uporabi zdravila zaradi razpoložljivosti več različnih tablet in jakosti odmerkov in vsebovati seznam vsebine kompleta za zdravnike, ki bodo zdravilo predpisovali.
The CR rate in first- relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45, 86) and the 4-month event free survival rate was 67% (95% CI: 42, 83).
Delež popolnih odgovorov pri prvih bolnikih s T-celično ALL (n = 22) je bil 68% (95% CI: 45, 86), delež 4-mesečnega preživetja bolnikov brez dogodkov pa 67% (95% CI: 42, 83).
The CR rate in first-relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45,
Delež popolnih odgovorov pri prvih bolnikih s T-celično ALL
The CR rate in first-relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45,
Delež popolnih odgovorov pri prvih bolnikih s T-celično ALL (n =
The cream is applied in a thin layer to the affected areas of skin before sleeping, so that it remains on the skin for a suitable length of time (about eight hours) before being washed off.
Krema se pred spanjem v tanki plasti nanaša na prizadeta mesta na koži, tako da ostane na koži primerno dolgo časa (približno osem ur), preden se spere.
The cream should not be applied more than once daily.
Kreme ne smete nanesti pogosteje kot enkrat na dan.
The cream should not be applied more than once daily.
Kreme ne uporabite pogosteje kot enkrat na dan.
The cream should remain on the skin overnight (for about eight hours) before being washed off.
Na koži mora ostati čez noč (približno osem ur), preden se spere.
The crizotinib starting dose should be adjusted to 250 mg taken orally once daily in patients with severe renal impairment not requiring peritoneal dialysis or haemodialysis.
Pri bolnikih s hudo okvaro ledvic (ki ne potrebujejo peritonealne dialize ali hemodialize) je treba začetni odmerek krizotiniba prilagoditi na 250 mg peroralno enkrat na dan.
The cryobag and any unused product or waste material contains genetically modified organisms and should be disposed of in accordance with local requirements.
Zamrzovalno vrečo in neuporabljeno zdravilo ali odpadni material, ki vsebuje gensko spremenjene organizme, zavrzite v skladu z lokalnimi predpisi.
The crystals have not been associated with medicinal product –induced renal injury.
Kristali niso bili povezani s poškodbo ledvic, povzročeno z zdravilom.
The CSF clearance rate of cytarabine is similar to the CSF bulk flow rate of 0.24 ml/min.
Stopnja očistka citarabina iz cerebrospinalne tekočine je 0,24 ml/min in je podobna hitrosti pretoka cerebrospinalne tekočine.
The CSF pharmacokinetics of ziconotide have been studied following one-hour IT infusions of 1 - 10 μg of ziconotide in patients with chronic pain.
Farmakokinetika zikonotida v cerebrospinalni tekočini je bila proučevana po enourni intratekalni infuziji 1–10 µg zikonotida, aplicirani bolnikom s kronično bolečino.
The CSR should also include a detailed safety analysis.
Poročilo o klinični študiji (CSR) mora vključevati tudi podrobno analizo varnosti.
The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m2) to 50% (300 mg/m2).
Kumulativno izločanje irinotekana in njegovih presnovkov (SN-38 in glukuronida SN-38) z žolčem in urinom v 48 urah po dajanju irinotekana pri dveh bolnikih je bilo v razponu med približno 25 % (100 mg/m2) in 50 % (300 mg/m2).
The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (> 400 mg/m2) would require more than 20 courses of Caelyx therapy over 40 to 60 weeks.
Za kumulativni odmerek, pri katerem bi kardiotoksičnost postala problem pri teh bolnikih (> 400 mg/m2), bi bilo potrebnih več kot 20 ciklov zdravljenja zdravilom Caelyx v času 40 do 60 tednov.
The cumulative exposure to Votubia (111 patients who took at least one dose of everolimus) up to a median duration of exposure of 204.9 weeks (range 8.1 to 253.7) was associated with a discontinuation rate due to ADRs of 7.2% (n=8/111).
Pri kumulativni izpostavljenosti zdravilu Votubia (111 bolnikov, ki so prejeli najmanj en odmerek everolimusa) z medianim trajanjem 204,9 tedna (v razponu od 8,1 do 253,7) je bil delež bolnikov, ki so z zdravljenjem prenehali zaradi pojava neželenih učinkov 7,2 % (n=8/111).
The cumulative exposure to Votubia (112 patients who took at least one dose of everolimus) up to a median duration of exposure of 204.1 weeks (range 2 to 278) was associated with a discontinuation rate due to ADRs of 7.1% (n=8/112).
Pri kumulativni izpostavljenosti zdravilu Votubia (112 bolnikov, ki so prejeli najmanj en odmerek everolimusa) z medianim trajanjem 204,1 tedna (v razponu od 2 do 278) je bil delež bolnikov, ki so z zdravljenjem prenehali zaradi pojava neželenih učinkov 7,1 % (n=8/112).
The cumulative frequencies of second malignancy are 5%, 10-12% and 13-14% following 5, 10 and 15 years respectively after diagnosis of hairy cell leukaemia.
Kumulativne pogostnosti sekundarnih malignomov so 5 %, 10–12 % in 13–14 % po 5, 10 oziroma 15 letih po diagnozi dlakavocelične levkemije.
The cumulative genotypic rates by week 104 were 25.1% (115/458) for HBeAg-positive patients and 10.8% (24/222) for HBeAg-negative patients.
Kumulativni deleži genotipske rezistence so bili po 104 tednih 25,1% (115/458) pri HBeAg- pozitivnih bolnikih in 10,8% (24/222) pri HBeAg-negativnih bolnikih.
The cumulative incidence of neutrophil recovery at day 28 was 98.8% (95%CI, 85.7-99.9%).
Kumulativna pojavnost obnove nevtrofilcev na 28. dan je bila 98,8 % (95-odstotni IZ 85,7– 99,6 %).
The cumulative probabilities of developing these adefovir- associated resistance mutations in all patients treated with adefovir dipivoxil were 0 % at 48 weeks and approximately 2 %, 7 %, 14 % and 25 % after 96, 144, 192 and 240 weeks, respectively.
Kumulativne verjetnosti razvoja teh mutacij za rezistenco povezanih z adefovirjem so bile pri vseh bolnikih zdravljenih z dipivoksiladefoviratom 0% v 48. tednu in približno 2% po 96 tednih, 7% po 144 tednih, 14% po 192 tednih in 25% po 240 tednih.
The cumulative response rates were higher throughout the open label phase in those patients receiving two consecutive OZURDEX injections compared with those patients who had not received an OZURDEX injection in the initial phase.
Hitrosti kumulativnega odziva so bile v celotni odprti fazi večje pri bolnikih, ki so prejeli dve zaporedni injiciranji zdravila OZURDEX, kot pri bolnikih, ki v začetni fazi niso prejeli injiciranja zdravila OZURDEX.
The cumulative review of bronchoconstriction identified 45 evaluable cases following regadenoson administration that did not have features of a hypersensitivity reaction.
Pri kumulativnem pregledu bronhokonstrikcije so opredelili 45 ocenljivih primerov po uporabi regadenozona, ki niso imeli značilnosti preobčutljivostne reakcije.
The cumulative review of hyponatremia/SIADH cases provided by the MAH identified a total of 29 cases (16 spontaneous reports and 13 SAEs from clinical studies) which contained at least one MedDRA Preferred Term from the broad Standardised MedDRA Query (SMQ) Hyponatraemia/syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH).
S kumulativnim pregledom primerov hiponatriemije/SIADH, ki jih je posredoval imetnik dovoljenja za promet je bilo skupno identificiranih 29 primerov (16 spontanih poročil in 13 poročil iz kliničnih študij), ki so vsebovali vsaj en MeDRA preferenčni termin iz široke Standardizirane MedDRA poizvedbe (SMQ- Standardised MedDRA Query) Hiponatriemija/sindrom neustreznega izločanja antidiuretičnega hormona (SIADH).
The cumulative time during which the syringe is kept at room temperature (25°C) must not exceed 4 hours.
Kumulativno obdobje, v katerem injekcijsko brizgo hranite pri sobni temperaturi (25 °C), ne sme presegati 4 ur.
The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.
Kumulativno se v prvih 48 urah z urinom izloči 66 % odmerka levetiracetama ter 24 % odmerka njegovega primarnega presnovka.
The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.
V prvih 48 urah se s kumulativnim izločanjem z urinom izloči 66 % odmerka levetiracetama ter 24 % odmerka njegovega primarnega presnovka.
The cup has lines to indicate each ml of solution.
Merica ima črtice, ki označujejo mililitre raztopine.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Študija CURE je vključevala 12.562 bolnikov z akutnim koronarnim sindromom brez elevacije ST- spojnice (nestabilna angina ali miokardni infarkt brez Q-zobca) do 24 ur po zadnji epizodi bolečine v prsih ali simptomih, konsistentnih z ishemijo.
The current dose of metformin and thiazolidinedione can be continued unchanged.
Trenutni odmerek metformina in tiazolidindiona lahko ostane nespremenjen.
The current understanding of the benefits and risks of cytoreductive surgery in the management of patients with malignant gliomas;
trenutnem razumevanju prednosti in tveganj citoreduktivne kirurgije pri obravnavanju bolnikov z malignimi gliomi;
The current warning in the SmPC outlines that the initial prescription and dispensing of Erivedge should occur within 7 days of a negative pregnancy test.
Trenutno opozorilo v SmPC navaja, da mora biti zdravilo Erivedge prvič predpisano in izdano v 7 dneh po negativnem testu nosečnosti.
The currently available data both in vitro and in patients suggest that HBV expressing the adefovir- associated resistance mutation rtN236T is susceptible to lamivudine.
Podatki, ki so trenutno na voljo tako in vitro kot pri bolnikih, kažejo, da je HBV z mutacijo rtN236T, povezano z rezistenco proti adefovirju, občutljiv za lamivudin.
The currently available evidence was sufficient to show that Zykadia could be of benefit in these circumstances, although further data to confirm this are awaited.
Dokazi, ki so trenutno na voljo, so zadoščali za ugotovitev, da bi bilo zdravilo Zykadia lahko koristno v teh okoliščinah, čeprav se za potrditev te ugotovitve pričakujejo nadaljnji podatki.
The customer or the user of the administration system can help prevent electromagnetic interference by maintaining a minimum distance between portable and mobile RF communications equipment (transmitters) and the administration system as recommended below, according to the maximum output power of the communication equipment.
Z vzdrževanjem spodaj priporočene minimalne razdalje med mobilno komunikacijsko RF opremo (oddajniki) ob največji moči oddajanja in aplikacijskim sistemom lahko uporabnik pomaga preprečiti elektromagnetne motnje.
The customer or the user of the administration system should assure that it is used in such an environment.
Uporabnik aplikacijskega sistema mora zagotoviti, da se uporablja v takem okolju.
The cut off point for discriminating between H. pylori negative and positive patients is set to an excess value of 3.5, i.e. <3.5 is negative and 3.5 is positive.
Mejna vrednost ("Cut Off Point") za razlikovanje med bolniki, ki so H.pylori negativni ali pozitivni, je določena z vrednostjo, ki presega 3,5, t.j. pri vrednosti < 3,5 gre za negativen rezultat, medtem ko so vrednosti  3,5 pozitiven rezultat.
The cut-off point of the dynamic test should be strict.
Mejna točka dinamičnega testa mora biti strogo določena.
The CVMP agreed that the periodic safety update report (PSUR) cycle for Aivlosin would be re- started for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at three yearly intervals.
Odbor CVMP se je strinjal, da se bo cikel rednih posodobljenih poročil o varnosti zdravila (PSUR) za zdravilo Aivlosin ponovno začel z oddajo šestmesečnih poročil (vključene so vse odobrene oblike zdravila) v obdobju naslednjih dveh let, ki mu bo sledila oddaja dveh letnih poročil za naslednji dve leti, po tem obdobju pa se bodo poročila oddajala v triletnih obdobjih.
The CVMP at their meeting on 14-16 May 2013 decided that one further renewal was required for the centrally authorised product Reconcile.
Na svoji seji od 14. do 16. maja 2013 je Odbor za zdravila za uporabo v veterinarski medicini odločil, da se za izdelek Reconcile, ki ima dovoljenje za promet, pridobljeno po centraliziranem postopku, zahteva eno dodatno podaljšanje.
The CVMP at their meeting on 8-10 April 2014 agreed that as the product with the revised inactivation process is only on the market in the EU/EEA since December 2012 and new quality specifications have been implemented in 2013 to prevent serious safety issues observed in the field, an assessment of the full impact of these changes is not possible at this moment.
CVMP se je na srečanju 8-10 aprila 2014 strinjal, da ker je zdravilo z revidiranim postopkom inaktivacije na tržišču EU/EEA šele od decembra 2012 in ker so bile nove kakovostne specifikacije za preprečitev resnih varnostnih težav, ki so jih opazili na tem področju, implementirane v letu 2013, ocena o celotnem vplivu teh sprememb v tem trenutku ni mogoča.
The CVMP concluded that the benefits of Acticam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Acticam be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Acticam pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično- skeletnih obolenjih, lajšanju pooperativne bolečine in vnetja po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah večje od z njim povezanih tveganj, in priporočil, da se za zdravilo Acticam odobri dovoljenje za promet.